Introduction
Sufficient bronchodilatation can be achieved by pressurized metered-dose inhalers (pMD1) with low inspiratory flow (l), because drug particle diameters depend on the physicochemical properties of the drug-additive mixture (2), but not on inspiratory flow. In contrast, in the Turbuhaler@ (TH), insp' oratory flow produces respirable particles by sucking large drug particles with turbulent airstream into an inhalation channel, where the particles break up (2,3). It has been shown that the proportion of respirable particles of budesonide (4) and the lung deposition of budesonide and terbutaline (4,5) can be improved by increasing inspisatory flow from about 30 to 60 1 min -1 (peak flow through TH, PIF-TH). Despite these results, Pedersen et al. (6) found the same bronchodilatatory effect of terbutaline with a PIF-TH of 31 and 60 1 min -', Newman et al. (5) , however, reported a non-significant lower effect with 28 compared to 57 1 min ~ I.
The majority of children reach a PIF-TH in the critical range between 30 and 60 I min -' (6) . It is conceivable that those with ins in the lower end of this range profit less from bronchodilatation by TH compared to pMD1. In two studies (7, 8) with 12 and 13 asthmatic children, respectively, a 15% rise of forced expiratory volume in 1 s (FEV,) was reached with pMDI and TH without a significant difference, but the finding that a certain threshold can be reached does not exclude gradual differences in the effect, which might be flow-dependent with TH, but perhaps not with pMD1.
The main aim of the following double-blind, double-dummy, placebo-controlled trial was to compare the effect of terbutaline inhaled through TH or pMD1 on lung function. A secondary aim was to evaluate the relationship between the inspiratory capacity of young asthmatics and the effect of terbutaline upon bronchodilatation for both devices. In addition to PIF, the authors determined the forced inspiratory flow at 50% vital capacity (FIF,,) Zapletal et al. (10) . 1. Means of differences in maximal flow at 50% vital capacity (timax 50%) before and after 0.5 mg terbutaline ( f SD). dvmax 50% values are plotted for quartiles of forced inspiratory volume in 1 s (FIV,) ascending from left to right for both pressurized metered-dose inhaler (pMD1) and Turbuhaler@ (TH) users. Calculation basis for quartiles: whole population (pMDI+ TH users, n=llS). P value indications: significant differences between pMD1 and TH groups (t-test, PcO.05) and for TH users between patients with FIV, above and below median (1.76 1) (t-test, PcO.05). n = Number of patients in each quartile (wholepopulation based). For one patient with pMD1, dprnax 50% could not be determined because of a cough artefact at post-bronchodilatation measurement.
allow comparison of its influence on their bronchodilatatory effects.
Effective bronchospasmolysis (BSL) was defined as having a minimum change of lung function values 10 min after terbutaline inhalation for at least one of the following parameters: R,, <I= -50%, FEV,> = + 15%, l?max 50 or 25 </= +25%. If sufficient bronchodilatation was not achieved, patients inhaled 0.4 mg fenoterol by pMD1 and measurements were repeated 10 min later to evaluate the maximal possible bronchodilatation.
STATISTICAL ANALYSIS
Data was fed into the computer twice to check for mistakes. SPSS for MS Windows 6.01 was used as software for all statistical tests. Metereddose inhaler and TH results were compared with Chi-square test (discrete data), Mann-Whitney U-test (non-normally distributed continuous data) or two sided t-test (normally distributed continuous data). Statistical significance was assumed at P<O.O5. To assess the relation between inspiratory performance and terbutaline effect on lung function, a multiple linear regression analysis was conducted, and the corresponding partial correlation coefficients were calculated (significance of coefficients: PcO.05, two sided).
Results
Forty-one of 59 pMD1 patients (69.5%) and 33 of 59 TH patients (55.9%) reached a significant BSL effect with 0.5 mg terbutaline (difference not significant). Of the remaining patients, 37 (14 pMD1, 23 TH) inhaled fenoterol, and seven Each column shows partial correlation coefficients for one of three inspiratory variables (FIVl, FIF,,, PIF) and relative bronchodilatatory effect (pmax 50% resp. FEV, after terbutaline in % of pmax 50% resp. FEV, after fenoterol), separately for pMD1 and TH. The correlation coefficients are adjusted for age, height, FEV, (%pred.), VCin (%pred.), VCin, RV (%TLC): *P<O.O5. pMD1 and 10 TH patients reacted (significantly) positively to it.
The p-MD1 was slightly more effective for most indicators of obstruction. The difference was statistically significant (BO.05) for A Pmax 50%. Results for selected parameters are presented in Table 4. higher inspiratory flow (FIV,) was linearly positively related to better bronchodilatation (dpmax 50%) in TH patients alone. The regression coefficient of A pmax 50% (1 s -') to FIV, (1) was 0.71, and the 95% confidence interval (CI) ranged from 0.19 to 1.22 (partial correlation coefficients, see Table 5 ). The effect of bronchodilatation was greater Thirty-seven patients, who did not reach sigwith higher inspiratory flow (FIV, 2 1.77 1) in nificant bronchodilatation with 0.5 mg terbuta-TH patients, but not in pMD1 patients (Fig. 1). line, inhaled 0.4 mg fenoterol 10 min later, which In the multiple regression, including other facwas assumed to be the dose necessary to reach tors of potential influence on the bronchodilatathe maximal possible bronchodilatation. This tory effect [grade of baseline obstruction, subgroup did not differ from the rest of the inspiratory vital capacity (VC3, height and age], patients, with the exception of a lower RAW, indicating a weaker obstruction at baseline (PcO.05). For these patients, the relative terbutaline effect as a percentage of the maximal possible (i.e. fenoterol) effect was calculated. There was no difference in the relative terbutaline effect between pMD1 and TH users. In both groups, lower inspiratory flow was nonsignificantly associated with lower relative terbutaline effect. After considering age, height and baseline obstruction, a significant correlation between FIF,, and relative terbutaline effect was found in TH users alone. The regression coefficient of FEV, terbutaline (% of fenoterol) to FIF,, (1 s -') was 34.53, and the 95% CI ranged from 1.64 to 67.42 (partial correlation coefficients, see Table 6 ).
Discussion
In this cohort of young outpatient asthmatics, bronchodilatation with 0.5 mg terbutaline was slightly, but (d pmax 50%) significantly, more effective with pMD1 than with TH. Like others (7, 8) , the present authors could not detect a difference between pMD1 and TH in terms of the number of subjects reaching a certain bronchodilatatory threshold (i.e. a 15% rise of FEV,), but a difference was found in the mean effect in larger groups, which may be a more sensitive means of statistical evaluation.
Inspiratory capacity, determined by spirometry without device immediately before inhalation, was associated with the bronchospasmolytic effect in TH users, but not in pMD1 users. In children with a FIV, below 1.77 1, mean bronchodilatatory effect was significantly lower than in those with higher FIV,.
As the flow during the inhalation manoeuvre was not measured, the authors cannot conclude that higher inspiratory flow through TH causes better bronchodilatation. The authors' conclusion is that children with better inspiratory capacity inhale terbutaline more effectively through the TH than children with weaker capacity. In contrast, inspiratory capacity does not seem to influence the efficacy of terbutaline when using a pMD1.
The study patients' FIV, and FIF,, were correlated better with the effect of TH use than their PIF. Even though flow through TH cannot [NFLLJENCEOF INSPIRAT~R~CAPACITYON BR~NCH~DILATATION 345 be predicted accurately from flow without TH (II), this may suggest that not only the PIF but also the inspiratory flow throughout the entire inspiratory range has an impact upon the effect of bronchodilatation via TH. This hypothesis would explain why some investigators who measured only PIF-TH did not find a difference in the effect at lower and higher inspiratory flows (6) . If the relation between inspiratory performance and the therapeutic effect of inhalable drugs is to be assessed in the future, FIV, and FIF,, should be monitored both with and without the inhalation devices. Although the regression coefficient calculated from these data theoretically allows the prediction of d pmax 50% from FIV,, the wide 95% CI indicates that this prediction would be of no practical value. Nevertheless, the data suggest that a simple spirometric assessment of the inspiratory capacity might help to identify children less qualified for the use of the TH.
